A Study of LY4064809 in Healthy Adult Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Eli Lilly and Company
Study ID
NCT07339735
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • LY4064809 Test Formulation — DRUG
    Administered orally
  • LY4064809 Reference Formulation — DRUG
    Administered orally

Study Details

The purpose of this study is to find out how much LY4064809 gets into the blood stream and how long it takes the body to get rid of it when it is given as two formulations. For each participant, the study will last about nine weeks. Participants will remain in the clinical research center for about one month.

Key Dates

First listed
Jan 14, 2026
Start date
Jan 12, 2026
Status verified
Apr 2026
Primary completion
Mar 19, 2026
Completion
Mar 19, 2026

Study Design

Enrollment
24 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4064809 Test
    LY4064809 test (Phase 3 formulation) formulation administered orally in one of two periods.
  • Experimental: LY4064809 Reference
    LY4064809 reference (Phase 1 formulation) formulation administered orally in one of two periods.

Primary Outcome Measure

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4064809 [ Time Frame: Predose on Day 1 Through Day 28 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Inc. - MadisonMadisonWisconsin53704-2526-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Inc. - Madison· Madison, WI

Related Studies